Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Eun Young Kim, Jin Gu Lee, Jung Mo Lee, Arum Kim, Hee Chan Yoo, Kibum Kim, Minji Lee, Chulho Lee, Gyoonhee Han, Jung Min Han, Yoon Soo Chang

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Objective: Leucyl-tRNA synthetase (LRS) is an aminoacyl-tRNA synthetase catalyzing ligation of leucine to its cognate tRNA and is involved in the activation of mTORC1 by sensing cytoplasmic leucine. In this study, the usefulness of LRS as a therapeutic target of non-small cell lung cancer (NSCLC) and the anticancer effect of the LRS inhibitor, BC-LI-0186, was evaluated. Methods: LRS expression and the antitumor effect of BC-LI-0186 were evaluated by immunohistochemical staining, immunoblotting, and live cell imaging. The in vivo antitumor effect of BC-LI-0186 was evaluated using Lox-Stop-Lox (LSL) K-ras G12D mice. Results: LRS was frequently overexpressed in NSCLC tissues, and its expression was positively correlated with mTORC1 activity. The guanosine-5’-triphosphate (GTP) binding status of RagB was related to the expression of LRS and the S6K phosphorylation. siRNA against LRS inhibited leucine-mediated mTORC1 activation and cell growth. BC-LI-0186 selectively inhibited phosphorylation of S6K without affecting phosphorylation of AKT and leucine-mediated co-localization of Raptor and LAMP2 in the lysosome. BC-LI-0186 induced cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3 and increase of p62 expression, showing that it has the autophagy-inducing property. BC-LI-0186 has the cytotoxic effect at nanomolar concentration and its GI50 value was negatively correlated with the degree of LRS expression. BC-LI-0186 showed the antitumor effect, which was comparable with that of cisplatin, and mTORC1 inhibitory effect in a lung cancer model. Conclusions: BC-LI-0186 inhibits the noncanonical mTORC1-activating function of LRS. These results provide a new therapeutic strategy for NSCLC and warrant future clinical development by targeting LRS.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Publication statusPublished - 2019 May 1

Bibliographical note

Funding Information:
This work was supported by the Global Frontier Project (grant numbers NRF-2013M3A6A40 72536 and NRF-2014M3A6A4074817) and the Basic Science Research Program (grant number 2018R1A6A1A03023718) through the National Research Foundation of Korea (NRF) funded by the Ministry of Education.

Publisher Copyright:
© The Author(s), 2019.

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this